transmembrane protein 132AGenealiases: GBP · HSPA5BP1
Q-omics provides the consensus-scored TMEM132A profile across patient tissues and cancer cell-line models. TMEM132A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM132A is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, TMEM132A RNA expression shows 18,505 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where TMEM132A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM132A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM132A survival associations across molecular data types. TMEM132A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM132A RNA expression–survival associations across cancer types. High TMEM132A expression shows unfavorable associations in KIRC, BLCA, UVM, MESO and KICH, but favorable associations in UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM132A RNA expression.
This table summarizes TMEM132A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM132A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM132A shows higher tumor expression in COAD, HNSC, BLCA, LUAD, KIRC and STAD. The COAD box plot shows higher TMEM132A RNA expression in tumor versus normal tissue (log2 FC = +2.502, t-test p < 0.001).
This table shows molecular features associated with TMEM132A in patient tissues and cancer cell lines. In patient samples, TMEM132A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM132A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
